Braeburn
Dr. Dennis H. Langer has served as a Director of several biotechnology, specialty pharmaceutical, and diagnostic companies, and has been CEO and/or co-founder of several healthcare companies. Previously, Dennis served as a Managing Partner of Phoenix IP Ventures, a private equity/venture capital firm specializing in life sciences. Prior to that, he was President, North America, of Dr. Reddy’s Laboratories. Dennis has also held several leadership positions at GlaxoSmithKline and its predecessor, SmithKline Beecham, including Senior Vice President of Research and Development. He was President and CEO of Neose Technologies, Inc., and also held R&D and marketing positions at Eli Lilly, Abbott, and Searle. He began his career as a Chief Resident at Yale University School of Medicine and held clinical fellowships at Harvard Medical School and the National Institutes of Health. He serves as a Director of Myriad Genetics, Inc., Dicerna Pharmaceuticals, Inc., Delcath Systems, Inc., and several private companies. He is a Clinical Professor in the Department of Psychiatry, Georgetown University School of Medicine.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Braeburn
Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder. They are committed to advancing next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of opioid use disorder faced by patients, healthcare professionals, payers and society.